TheTechno Optimist.

TRIAD (Test of Rapamycin in Aging Dogs)Dog Aging Project—TRIAD enrollment surpasses 235 dogs as rapamycin trial progresses

TRIAD (Test of Rapamycin in Aging Dogs)

by Dog Aging ProjectUS

A randomized double-blind trial testing if rapamycin extends lifespan in dogs. First lifespan-endpoint drug trial in a pet animal.

PilotStage 3 of 5

Ongoing enrollment and dosing phase; targeting 580 dogs enrolled by end of 2026; study concludes 2029.

Updated Jun 2026Checked 10 Oct0 updates this week

Milestones

Next · Target enrollment of 580 dogs reached
  1. $7M NIH grant awarded to expand TRIAD studyJan 2025Complete.
  2. TRIAD protocol published in peer-reviewed literatureFeb 2025Complete.
  3. First 35 dogs complete baseline cognitive assessments2024Complete.
  4. 223 dogs enrolled and in active dosing phaseJun 2026Complete.
  5. Target enrollment of 580 dogs reachedTarget Dec 2026Current milestone.
  6. Study concludes with lifespan analysisTarget 2029Not yet reached.

Most important updates

Upcoming

  1. Dec 2026Target enrollment of 580 dogs reachedin about 7 weeks (next)
  2. 2029Study concludes with lifespan analysis
Primer